BTG Pactual Asset Management US’s Royalty Pharma RPRX Stock Holding History

BTG Pactual Asset Management US’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.97M	Buy	70,732 +11,073	+19%	+$576K	0.25%	92
2026 Q1	$2.86M	Sell	59,659 -7,035	-11%	-$308K	0.25%	90
2025 Q4	$2.58M	Buy	66,694 +5,563	+9%	+$212K	0.25%	75
2025 Q3	$2.16M	Buy	+61,131	New	+$2.21M	0.1%	74
2025 Q2	–	Sell	-76,943	Closed	-$2.4M	–	329
2025 Q1	$2.4M	Sell	76,943 -11,641	-13%	-$369K	0.26%	89
2024 Q4	$2.36M	Sell	88,584 -2,357	-3%	-$62.5K	0.25%	93
2024 Q3	$2.57M	Buy	+90,941	New	+$2.52M	0.22%	99

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BTG Pactual Asset Management US's RPRX Position: Q2 2026 in Review

BTG Pactual Asset Management US increased its Royalty Pharma (RPRX) stake by 19% in Q2 2026, buying an estimated $576K and bringing the position to 70,732 shares worth $3.97M. The position accounts for 0.25% of the portfolio, ranked #92.

BTG Pactual Asset Management US first reported a position in RPRX in Q3 2024 and has held it in 7 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

BTG Pactual Asset Management US held 70,732 shares of Royalty Pharma worth $3.97M as of Q2 2026.
BTG Pactual Asset Management US bought 11,073 Royalty Pharma shares in Q2 2026, an estimated $576K.
Royalty Pharma made up 0.25% of BTG Pactual Asset Management US's portfolio in Q2 2026, its #92 holding.
BTG Pactual Asset Management US first reported a position in Royalty Pharma in Q3 2024 and has held it in 7 quarters since.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on BTG Pactual Asset Management US's 13F filing for Q2 2026, filed 14 Aug 2026.